- ETST
is focused on its developing role as an international leader in the CBD
space
- The
company recently filed a securities registration statement with the SEC
- ETST
recently named a pharmaceutical and orthopedic expert as head of its new
sales division
Earth Science Tech Inc. (OTCQB: ETST) is an innovative
science-based biotechnology company operating in the fields of hemp-derived
cannabinoids, nutraceuticals, pharmaceuticals, medical devices and research and
development (R&D). The company, based in Doral, Florida, recently announced
its establishment of a new sales division specifically focusing on CBD products
of therapeutic and pharmaceutical grades.
The company’s CBD (cannabidiol) oil is 100 percent natural
and organic. In contrast to its competitors, which may use dangerous hemp
extraction methods including toxic solvents or high heat, ETST’s CBD-rich hemp
does not contain any synthetic cannabinoids and is not an isolate. Through its
subsidiaries, Earth Science Tech is focused on developing its role as a world
leader in the CBD space.
The impetus behind this new division comes from increased
interest in CBD products across multiple medical communities, including
medical, holistic and alternative medicine (http://ibn.fm/ugOM9). The division will be headed by Erika
Franck, who has been serving as the company’s clinical and therapeutics sales
director for several weeks. In her new role, Franck will be working with
medical providers, chiropractors, acupuncturists, holistic wellness
practitioners and veterinarians, utilizing her years of experience in the
medical field to bring the benefits of CBD to a myriad of industries.
Franck’s expertise includes CNS (central nervous system),
psychiatry, cardiology, pulmonology, asthmas, allergy and dermatology, which
she cultivated through working in the pharmaceuticals and orthopedics industry
for over 15 years. During her time in pharmaceuticals, Franck launched two new
drugs into the medical market: Lexapro (a type of antidepressant) and Benicar
(a drug used to treat high blood pressure).
“I am thrilled to be part of this amazing team and to have
the opportunity to apply my expertise in spearheading this new clinical
division for ETST,” Franck said in a news release. “Our shared vision is to
improve patients’ quality of life, and I am honored to participate in ETST’s
growth as we achieve this mission.”
ETST president, director, and chairman Nickolas Tabraue
announced his excitement at adding Franck’s leadership experience to the
division. “She brings a wealth of knowledge and experience to the team that
will be invaluable as we pursue opportunities through this exciting new sales
channel,” Tabraue added. “We pride ourselves on hiring the very best and
brightest, and Erika certainly fits that criteria.”
Recently, ETST filed its Form S-1/A securities registration
statement (http://ibn.fm/7ebl1).
It was filed with the U.S. Securities and Exchange Commission (SEC) on
September 10, 2019. The document details the company’s long-term strategy,
partnerships and strategic focus, as well as providing an overview of its
subsidiaries.
The company continues to expand its work in the
pharmaceutical and medical device sectors through its subsidiaries, which
include Nutrition Empire Inc., Earth Science Pharmaceutical Inc., Cannabis
Therapeutics Inc. (CTI), and KannaBidioiD (KBD). ETST also has its Canadian
subsidiary, Canna Inno Laboratories Inc.
ETST continues to focus on the CBD market with its broad
array of well-branded products and premier distribution. For investors, the
company has a strong in-house team and strategic partnerships to foster
continued growth. ETST is advancing further projects using its high-grade and
inventive products.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates
relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
